Charles River Laboratorie... (CRL)
105.58
5.83 (5.84%)
At close: Apr 14, 2025, 12:34 PM
5.84% (1D)
| Bid | 105.41 |
| Market Cap | 5.19B |
| Revenue (ttm) | 4.05B |
| Net Income (ttm) | 12.25M |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 527.9 |
| Forward PE | 16.58 |
| Analyst | Hold |
| Ask | 105.75 |
| Volume | 1,415,270 |
| Avg. Volume (20D) | 1,521,163 |
| Open | 104.08 |
| Previous Close | 99.75 |
| Day's Range | 100.22 - 106.67 |
| 52-Week Range | 91.86 - 254.15 |
| Beta | 1.45 |
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent r...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jun 23, 2000
Employees 18,700
Stock Exchange NYSE
Ticker Symbol CRL
Website https://www.criver.com
Analyst Forecast
According to 14 analyst ratings, the average rating for CRL stock is "Hold." The 12-month stock price forecast is $174, which is an increase of 64.80% from the latest price.
Stock ForecastsNext Earnings Release
Charles River Laboratories International Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-28.13%
Charles River Laboratories shares are trading high...
Unlock content with
Pro Subscription
3 months ago
-6.34%
Charles River Laboratories shares are trading lower after the company announced a year-over-year decrease in preliminary FY25 revenue.
